Allergan Inc (AGN)

AGN on New York Consolidated

212.18USD
18 Dec 2014
Price Change (% chg)

$4.15 (+1.99%)
Prev Close
$208.03
Open
$210.50
Day's High
$213.61
Day's Low
$209.54
Volume
2,848,972
Avg. Vol
3,160,052
52-wk High
$214.66
52-wk Low
$98.78

AGN

Chart for AGN

About

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company’s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye,... (more)

Overall

Beta: 0.76
Market Cap (Mil.): $61,971.85
Shares Outstanding (Mil.): 297.90
Dividend: 0.05
Yield (%): 0.10

Financials

  AGN Industry Sector
P/E (TTM): 48.49 36.60 37.24
EPS (TTM): 4.29 -- --
ROI: 13.72 18.95 18.21
ROE: 19.71 19.73 19.11
Search Stocks

Ackman's Pershing Square sees big payoff from Allergan deal

BOSTON - Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

26 Nov 2014

UPDATE 1-Ackman's Pershing Square sees big payoff from Allergan deal

(Adds details from Ackman's letter about other investments)

26 Nov 2014

Ackman's Pershing Square still holds 26.6 million Allergan shares

BOSTON, Nov 26 - Hedge fund manager William Ackman told investors in a letter that his firm still owns 26.6 million shares in Allergan Inc. which were valued at $5.6 billion one week after the Botox maker agreed to sell itself to rival pharmaceutical company Actavis Plc.

26 Nov 2014

Actavis mulls job cuts, China expansion: Bloomberg

- Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

24 Nov 2014

A

21 Nov 2014

CORRECTED-BRIEF-Valeant Pharma reports 0.1 percent stake in Allergan

(Corrects first bullet point to remove incorrect reference to Valeant's prior stake in Allergan)

21 Nov 2014

Valeant slashes stake in Allergan after losing bid

- (Refiles Nov. 20 story to correct reference to previous stake)

21 Nov 2014

CORRECTED-Valeant slashes stake in Allergan after losing bid

Nov 20 - Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent, three days after Actavis Plc trumped its offer for the Botox maker.

21 Nov 2014

Suvretta's Cowen says Actavis stock could nearly double

NEW YORK - After months of fending off a hostile bid, Allergan Inc Chief Executive David Pyott made the right call in selling to rival Actavis Plc , whose stock price could nearly double in the next two years, a prominent investor said on Wednesday.

19 Nov 2014

Markets up on Japanese stimulus hopes; Wall Street at new highs

NEW YORK - Stock markets around the world rose on Tuesday and the yen hit a seven-year low as news of a snap election and a delayed tax increase in Japan bolstered hopes for new stimulus measures a day after data showed the country was back in recession.

18 Nov 2014

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,696 +41.50
Santen Pharmaceutical Co Ltd (4536.T) ¥6,530 +160.00
Lupin Limited (LUPN.NS) Rs1,425.55 --
Nestle SA (NESN.VX) CHF71.40 +1.40
Johnson & Johnson (JNJ.N) $106.81 +2.74
Pfizer Inc. (PFE.N) $31.97 +0.85
Novartis AG (NOVN.VX) CHF92.10 +3.15
High Tech Pharm Co.,Ltd. (106190.KQ) ₩13,800.00 +150.00
Merck & Co., Inc. (MRK.N) $58.98 +1.35
Roche Holding Ltd. (ROG.VX) CHF288.70 +9.70

Earnings vs. Estimates

Search Stocks